InflammX Therapeutics is focused on developing innovative therapies targeting the NLRP3 inflammasome pathway, which plays a crucial role in various autoinflammatory diseases. Their lead product, Xiflam™, is a small molecule designed for once-daily oral administration. It specifically targets the pathologically open Connexin43 (Cx43) hemichannel, which is implicated in the dysregulation of the inflammasome and contributes to conditions such as Diabetic Macular Edema (DME), Diabetic Chronic Kidney Disease (CKD), and intermediate Age-related Macular Degeneration (iAMD). By modulating the Cx43 hemichannel, Xiflam™ aims to inhibit the release of ATP, a key activator of the inflammasome, thereby breaking the cycle of chronic inflammation and offering a potential therapeutic solution for these diseases.

The underlying mechanism of InflammX's technology involves the regulation of upstream activation signals that lead to the assembly of the NLRP3 inflammasome complex. Under pathological conditions, the premature opening of Cx43 hemichannels results in excessive ATP release, triggering a cascade of inflammatory responses that can cause significant tissue damage. InflammX's approach with Xiflam™ seeks to close these aberrantly open hemichannels, reducing the inflammatory signal and allowing for a return to physiological homeostasis. This novel strategy not only addresses the immediate inflammatory response but also holds promise for regenerative processes in affected tissues, potentially transforming the treatment landscape for diseases characterized by inflammasome-mediated autoinflammation.

United States

InflammX Therapeutics, Inc. is targeting inflammasome mediated and recycling inflammation, and providing a therapeutic effect to both eyes simultaneously. They have a pipeline focused on ophthalmic treatments and have submitted an IND amendment to enable clinical studies with orally dosed Xiflam, their NLRP3 inflammasome targeting program in retinal and kidney disease.

InflammX Therapeutics

Company Details